Gilead Sciences presents a moderately bullish thesis with a trailing P/E of 17.4, market capitalization of $158.8 billion, TTM EPS of $7.35, and 4.4% year-over-year quarterly revenue growth to $29.7 billion. The stock trades at a forward P/E of 15.22 with a 2.58% dividend yield, supported by strong profitability margins of 31% and return on equity of 43.4%. Analyst consensus leans positive with 24 buy ratings versus 7 holds and a target price of $157.57, implying upside from current levels near the 50-day moving average of $130.31. Key catalysts include robust earnings momentum with 54.8% quarterly EPS growth, upcoming dividend payment on June 29, 2026, and pipeline expansion in antiviral therapies for HIV and hepatitis. The company benefits from established products like Harvoni and Sovaldi driving revenue per share of $23.92, alongside potential market expansion in oncology and inflammation. Institutional ownership at 92.2% and insider alignment further support sustained growth in the biopharmaceutical sector. Risks center on regulatory hurdles for new drug approvals, intense competition from peers in the drug manufacturing industry, and macroeconomic pressures such as healthcare policy changes or inflation impacting R&D costs. Mitigation comes from diversified revenue streams, a solid balance sheet with $14.7 billion EBITDA, and a beta of 0.33 indicating lower volatility than the broader market. Ongoing focus on high-margin antivirals helps buffer against sector headwinds. Analysis generated by HeyTheo AI based on SEC filings, earnings transcripts, and market data.